[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 35 of about 35
1. Lin JC, Jan JS, Hsu CY, Jiang RS, Wang WY: Outpatient weekly neoadjuvant chemotherapy followed by radiotherapy for advanced nasopharyngeal carcinoma: high complete response and low toxicity rates. Br J Cancer; 2003 Jan 27;88(2):187-94
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outpatient weekly neoadjuvant chemotherapy followed by radiotherapy for advanced nasopharyngeal carcinoma: high complete response and low toxicity rates.
  • The aim of this prospective study is to evaluate the toxicity and efficacy of an outpatient weekly neoadjuvant chemotherapy (NeoCT) plus radiotherapy for advanced NPC.
  • (2) supraclavicular node metastasis;.
  • (3) skull base destruction/intracranial invasion plus multiple nodes metastasis;.
  • (4) multiple neck nodes metastasis with one of nodal size >4 cm; or (5) elevated serum LDH level.
  • Local radiotherapy > or =70 Gy by conventional fractionation was delivered within 1 week after NeoCT.
  • After a median follow-up time of 24 months, one persistent disease and 18 relapses were noted.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness / pathology. Neoplasm Staging. Outpatients. Patient Compliance. Prospective Studies. Survival Rate. Treatment Failure

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):901-5 [10571196.001]
  • [Cites] Radiology. 1999 May;211(2):513-8 [10228536.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1323-30 [11121629.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1105-10 [11181675.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1350-7 [11230478.001]
  • [Cites] J Clin Oncol. 2001 Dec 1;19(23):4305-13 [11731513.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1238-44 [11955734.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2038-44 [11956263.001]
  • [Cites] Cancer. 2002 Apr 15;94(8):2217-23 [12001120.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Oct;11(10):1789-93 [2412999.001]
  • [Cites] J Clin Oncol. 1988 Sep;6(9):1401-10 [3047335.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):261-70 [1587745.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Oct 15;33(3):569-77 [7558945.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jun 1;35(3):463-9 [8655368.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):1127-36 [8985035.001]
  • [Cites] Cancer. 1997 Apr 1;79(7):1279-86 [9083147.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):985-96 [9169804.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1310-7 [9552031.001]
  • [Cites] Cancer. 1998 Dec 1;83(11):2270-83 [9840526.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):261-71 [10030248.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1277-9 [11121623.001]
  • (PMID = 12610501.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Number-of-references] 22
  • [Other-IDs] NLM/ PMC2377053
  •  go-up   go-down


2. Lee JI, Kim YZ, Lee EH, Kim KH: Skull base invasion of adenoid cystic carcinoma of the lacrimal gland : a case report. J Korean Neurosurg Soc; 2008 Oct;44(4):273-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skull base invasion of adenoid cystic carcinoma of the lacrimal gland : a case report.
  • Additionally, he received radiotherapy (60 Gy) and adjuvant systemic cisplatin and 5-fluorouracil chemotherapy due to residual tumor in the orbit and systemic metastases (lung, ribs, and spines).
  • He was free of progression and recurrence at 6 months after treatment.
  • The authors report a case of skull base invasion by an ACC of the lacrimal gland to remind neurosurgeons planning intervention that this disease shows a tendency to invade intracranially.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Oncol. 2005 Mar;41(3):328-35 [15743696.001]
  • [Cites] Brain Tumor Pathol. 2000;17(3):159-63 [11310924.001]
  • [Cites] Arch Ophthalmol. 1998 May;116(5):613-6 [9596497.001]
  • [Cites] Arch Ophthalmol. 1998 Mar;116(3):315-21 [9514484.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):867-9 [8922205.001]
  • [Cites] Neurosurgery. 1996 Jun;38(6):1105-12; discussion 1112-3 [8727139.001]
  • [Cites] Br J Ophthalmol. 1992 Jul;76(7):401-7 [1320924.001]
  • [Cites] Ear Nose Throat J. 1991 Apr;70(4):218-22 [1651839.001]
  • [Cites] Can J Ophthalmol. 1982 Feb;17(1):3-9 [6282425.001]
  • [Cites] Br J Ophthalmol. 1979 Sep;63(9):600-6 [486378.001]
  • [Cites] Am J Ophthalmol. 1975 Jan;79(1):53-5 [162900.001]
  • [Cites] Ear Nose Throat J. 2002 Aug;81(8):510-4, 516-7 [12199167.001]
  • [Cites] Otolaryngol Clin North Am. 2001 Dec;34(6):1079-85, viii [11728933.001]
  • [Cites] Br J Plast Surg. 2001 Jul;54(5):467 [11428792.001]
  • [Cites] Pathol Int. 1998 Dec;48(12):981-4 [9952343.001]
  • (PMID = 19096692.001).
  • [ISSN] 2005-3711
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2588318
  • [Keywords] NOTNLM ; Adenoid cystic carcinoma / Metastasis / Prognosis / Skull base
  •  go-up   go-down


3. Isaka T, Maruno M, Suzuki T, Sato M, Yoshimine T: Skull metastases from atypical pulmonary carcinoid tumor in a 19-year-old man. Neurol Med Chir (Tokyo); 2006 Dec;46(12):609-13
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skull metastases from atypical pulmonary carcinoid tumor in a 19-year-old man.
  • A 19-year-old man presented with a rare skull metastasis from atypical pulmonary carcinoid tumor (APCT) manifesting as headache, diplopia, and cough.
  • Head magnetic resonance imaging showed a skull base tumor extending from the posterior clinoid process to the clivus, and calvarial tumors in the right temporal and occipital bones.
  • Chest and abdominal computed tomography showed a round tumor, 4 cm in diameter, in the lower lobe of the right lung and multiple small tumors in the liver.
  • The histological diagnosis was skull metastasis of neuroendocrine tumor.
  • Gamma knife radiosurgery was performed for the residual skull metastases.
  • The histological diagnosis was atypical carcinoid tumor.
  • Subsequent adjuvant systematic chemotherapy was performed.
  • We must consider APCT in the differential diagnosis of pulmonary tumors in adolescents, and perform follow-up observation or treatment, including surgery, if APCT is suspected.
  • [MeSH-major] Carcinoid Tumor / secondary. Lung Neoplasms / pathology. Skull Neoplasms / secondary

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17185889.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Laigle-Donadey F, Taillibert S, Martin-Duverneuil N, Hildebrand J, Delattre JY: Skull-base metastases. J Neurooncol; 2005 Oct;75(1):63-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skull-base metastases.
  • Metastasis to the skull-base particularly affects patients with carcinoma of the breast and prostate.
  • Magnetic resonance imaging (MRI) is nowadays the most useful examination to establish the diagnosis but plain films, CT scans with bone windows and isotope bone scans remain helpful to demonstrate bone erosion.
  • Normal imaging studies do not exclude the diagnosis.
  • The treatment depends on the nature of the underlying tumor.
  • Radiotherapy is generally the standard treatment, while some patients with chemosensitive or hormonosensitive lesions benefit from chemotherapy or hormonotherapy and selected patients from surgical removal.
  • Gamma Knife radiosurgery is sometimes a useful alternative, particularly for previously irradiated skull-base regions, and for small tumors (diameter < 30 mm).
  • The overall prognosis is poor, with an overall median survival of about 2.5 years, probably because skull-base metastases appear late in the course of the disease.
  • [MeSH-major] Skull Base Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1964 Jun;21:447-60 [14171303.001]
  • [Cites] Can J Neurol Sci. 1985 Nov;12(4):336-40 [4084873.001]
  • [Cites] Am J Surg. 1987 Oct;154(4):352-8 [3661836.001]
  • [Cites] No Shinkei Geka. 1987 Jul;15(7):765-9 [3670546.001]
  • [Cites] Rev Neurol. 1997 Jul;25(143):1092-4 [9280644.001]
  • [Cites] Cancer. 1987 Jun 1;59(11):1887-91 [3567852.001]
  • [Cites] J Neurol. 1998 Feb;245(2):98-100 [9507415.001]
  • [Cites] Curr Neurol Neurosci Rep. 2002 Sep;2(5):423-31 [12169223.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1990 Jul;53(7):613-4 [2391528.001]
  • [Cites] Arch Intern Med. 1963 Dec;112:819-21 [14056846.001]
  • [Cites] Stereotact Funct Neurosurg. 1999;72 Suppl 1:81-7 [10681695.001]
  • [Cites] Clin Radiol. 1998 Jun;53(6):405-16 [9651055.001]
  • [Cites] Neurology. 1990 Jun;40(6):997-9 [2345622.001]
  • [Cites] HNO. 2002 Feb;50(2):165-8 [12080628.001]
  • [Cites] Cancer. 1990 Feb 1;65(3):586-9 [2297648.001]
  • [Cites] Hong Kong Med J. 2002 Feb;8(1):48-51 [11861994.001]
  • [Cites] Cancer. 1992 Aug 15;70(4):877-81 [1643620.001]
  • [Cites] Headache. 2002 Feb;42(2):142-6 [12005291.001]
  • [Cites] J Clin Neuroophthalmol. 1992 Sep;12(3):149-53 [1401157.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1973 Apr;36(2):211-6 [4708456.001]
  • [Cites] Neurol Med Chir (Tokyo). 1992 Nov;32(12):908-10 [1282684.001]
  • [Cites] Arch Neurol. 1983 Dec;40(13):816-8 [6639410.001]
  • [Cites] Br J Urol. 1988 May;61(5):441-4 [3395804.001]
  • [Cites] Arch Neurol. 1996 Jun;53(6):561-6 [8660159.001]
  • [Cites] Can J Neurol Sci. 1985 Nov;12(4):327-31 [4084871.001]
  • [Cites] Neurology. 1992 Jun;42(6):1181-4 [1603345.001]
  • [Cites] No Shinkei Geka. 1996 Sep;24(9):829-33 [8827733.001]
  • [Cites] J Assoc Physicians India. 2000 Aug;48(8):850-1 [11273489.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1179-87 [12973841.001]
  • [Cites] Neurosurgery. 1992 Oct;31(4):783-6; discussion 786 [1407469.001]
  • [Cites] Radiology. 1979 Feb;130(2):465-8 [104361.001]
  • [Cites] Neurochirurgie. 2001 Feb;47(1):61-5 [11283458.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):997-1003 [9169805.001]
  • [Cites] No To Shinkei. 1980 Jul;32(7):695-700 [7407020.001]
  • [Cites] Neurology. 1981 Aug;31(8):998-1002 [7196526.001]
  • [Cites] Cancer. 1983 Jul 1;52(1):180-4 [6850542.001]
  • [Cites] Australas Radiol. 2001 Nov;45(4):534-5 [11903195.001]
  • [Cites] Am J Ophthalmol. 1995 Jun;119(6):779-85 [7785694.001]
  • [Cites] Clin Neurol Neurosurg. 2000 Sep;102(3):149-55 [10996713.001]
  • [Cites] J Korean Med Sci. 2000 Jun;15(3):363-7 [10895984.001]
  • [Cites] Rev Neurol. 1999 Nov 16-30;29(10 ):929-32 [10637842.001]
  • [Cites] J Neurosurg. 2002 Dec;97(5 Suppl):674-6 [12507118.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 1998 Oct;78(10):761-2 [11038829.001]
  • [Cites] Naika. 1970 Oct;26(4):755-7 [5470882.001]
  • [Cites] Neurology. 1981 May;31(5):530-7 [6972014.001]
  • [Cites] Arch Ophthalmol. 1988 Oct;106(10):1403-8 [3178551.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1985 Dec;48(12):1305-6 [4087010.001]
  • [Cites] Neurologia. 1989 Oct;4(8):277-81 [2637769.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 2000 Jun;91(6):562-4 [10897582.001]
  • [Cites] Eye (Lond). 2002 Nov;16(6):749-53 [12439671.001]
  • [Cites] Headache. 1998 Apr;38(4):308-11 [9595872.001]
  • [Cites] Cancer. 1983 Nov 1;52(9):1739-47 [6616423.001]
  • [Cites] HNO. 2001 Feb;49(2):126-9 [11270194.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Dec 1;39(5):977-81 [9392534.001]
  • [Cites] Arch Ophthalmol. 1974 Oct;92(4):276-86 [4412321.001]
  • [Cites] J Neurosurg. 1981 Sep;55(3):463-6 [7264738.001]
  • [Cites] Intern Med. 2001 Sep;40(9):924-30 [11579958.001]
  • [Cites] Clin Neurol Neurosurg. 2003 Jul;105(3):170-4 [12860509.001]
  • [Cites] Ann Nucl Med. 1998 Aug;12 (4):213-6 [9795708.001]
  • [Cites] Ann Intern Med. 1969 Jan;70(1):49-54 [4303303.001]
  • [Cites] Urology. 1988 Mar;31(3):211-3 [3126588.001]
  • [Cites] Arch Soc Esp Oftalmol. 2003 Jan;78(1):43-6 [12571774.001]
  • [Cites] J Comput Assist Tomogr. 1985 Jan-Feb;9(1):115-20 [2981908.001]
  • [Cites] Neurology. 1963 Sep;13:797-809 [14064314.001]
  • [Cites] Orbit. 2002 Dec;21(4):307-10 [12610771.001]
  • [Cites] J Neurosurg. 1985 May;62(5):776-80 [3989599.001]
  • [Cites] Neurologia. 1989 Oct;4(8):293-5 [2637770.001]
  • [Cites] Am J Ophthalmol. 2002 Nov;134(5):785-7 [12429268.001]
  • [Cites] Cancer. 1970 Feb;25(2):478-80 [5413515.001]
  • [Cites] Neurology. 1986 Jun;36(6):745-9 [3703281.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1975 Jan;123(1):13-21 [164131.001]
  • [Cites] Actas Urol Esp. 1994 Oct;18(9):911-4 [7817864.001]
  • [Cites] No Shinkei Geka. 1996 Mar;24(3):235-9 [8851952.001]
  • [Cites] South Med J. 1984 Jan;77(1):92-3 [6695231.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1984 May;47(5):558-60 [6547477.001]
  • [Cites] Neurology. 1981 Oct;31(10):1277-81 [6287347.001]
  • [Cites] Can J Neurol Sci. 1985 Nov;12(4):363-5 [3936612.001]
  • [Cites] Arch Neurol. 1980 Jan;37(1):59-61 [7350906.001]
  • [Cites] Cancer. 1994 May 1;73(9):2395-9 [8168043.001]
  • [Cites] Isr Med Assoc J. 2002 Oct;4(10):829-31 [12389355.001]
  • [Cites] Br J Radiol. 1999 Oct;72 (862):933-41 [10673942.001]
  • [Cites] Neurologia. 2000 Jan;15(1):31 [10730064.001]
  • [Cites] Cancer. 1993 Feb 1;71(3):874-5 [8431871.001]
  • [Cites] J Neurol Sci. 1997 May 1;148(1):127-9 [9125401.001]
  • [Cites] Radiographics. 1997 Sep-Oct;17 (5):1111-21 [9308105.001]
  • [Cites] Br J Ophthalmol. 1988 Apr;72 (4):248-52 [3288277.001]
  • [Cites] Surg Neurol. 2003 Sep;60(3):219-25; discussion 225-6 [12922038.001]
  • (PMID = 16215817.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 92
  •  go-up   go-down


5. Kamiński B, Kobiorska-Nowak J, Bień S: [Distant metastases to nasal cavities and paranasal sinuses, from the organs outside the head and neck]. Otolaryngol Pol; 2008;62(4):422-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At that time, the correct diagnosis requires only to compare the pathology report from the primary biopsy, with the biopsy from the lump in the head and neck.
  • Case I. F. 71 years; the metastasis of colonic carcinoma to the sphenoid sinus as a first symptom of the disease).
  • The palliative Rtg-therapy was applied, and patient died in 2 months after diagnosis was established.
  • Case II. M. 69 y with metastasis of kidney cancer (Ca clarocellulare) to the nasal cavity, during a palliative stage of the disease due to multiple lung metastases.
  • Patient was treated with multiple courses of chemotherapy due to generalization of the disease.
  • The nasal cavity metastasis was treated with repeated local resections.
  • At present with no metastasis within the head and neck region--alive, in relatively good condition, with 23 months of observation.
  • Cases III. F. 50 years in palliative stage of the breast cancer, with metastases to the bones and hepar and with metastasis to the maxillary sinus.
  • Received palliative Rtg. therapy on the region of metastasis.
  • Died in 5 months after diagnosis of maxillary sinus metastasis.
  • Case IV. F. 54 years in palliative stage of the colonic cancer, with multiple metastases to the lungs and hepar; with metastasis to the maxillary sinus.
  • During hemotherapy a symptoms of tumor of the maxillary sinus appeared, confirmed as a metastasis.
  • The palliative Rtg-therapy on the region of metastasis.
  • Died in 18 months, after diagnosis of maxillary sinus metastasis.
  • In the majority of distant metastases to the nose and paranasal sinuses, the palliative therapy is the only possible option of treatment.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Renal Cell / pathology. Colonic Neoplasms / pathology. Paranasal Sinus Neoplasms / secondary. Skull Base Neoplasms / secondary
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Poland. Prognosis. Survival Analysis. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18837216.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


6. Pavithran K, Doval DC, Hukku S, Jena A: Isolated hypoglossal nerve palsy due to skull base metastasis from breast cancer. Australas Radiol; 2001 Nov;45(4):534-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated hypoglossal nerve palsy due to skull base metastasis from breast cancer.
  • We describe a 44-year-old woman who presented with an isolated unilateral hypoglossal nerve paralysis caused by a skull base metastasis from breast cancer.
  • The patient had a modified radical mastectomy followed by local radiotherapy and adjuvant chemotherapy.
  • [MeSH-major] Breast Neoplasms / pathology. Cranial Nerve Neoplasms / etiology. Hypoglossal Nerve Diseases / etiology. Skull Base Neoplasms / secondary

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11903195.001).
  • [ISSN] 0004-8461
  • [Journal-full-title] Australasian radiology
  • [ISO-abbreviation] Australas Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


7. Zanation AM, Ferlito A, Rinaldo A, Gore MR, Lund VJ, McKinney KA, Suárez C, Takes RP, Devaiah AK: When, how and why to treat the neck in patients with esthesioneuroblastoma: a review. Eur Arch Otorhinolaryngol; 2010 Nov;267(11):1667-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Esthesioneuroblastoma is an uncommon tumor that presents in the sinonasal cavity and anterior skull base.
  • This presents the treating physician with the difficult decision as to how and when to treat the neck in this disease.
  • The aims of this study were to provide a comprehensive review of the incidence of N+ disease at presentation, make recommendations about the optimal treatment strategy of patients with N+ disease, explain the role of elective neck treatment in patients with N0 disease, and comment on treatment of patients with late cervical metastases that require salvage therapy, using the literature review of the incidence and treatment of neck disease in patients with esthesioneuroblastoma.
  • This review revealed an approximately 5-8% incidence of cervical nodal metastasis at the time of presentation.
  • Combined modality therapy with surgery and radiotherapy is recommended to treat the N+ neck at the time of diagnosis and later.
  • Chemotherapy may have a role combined with radiation treatment, but there are little data to support this.
  • The results indicate that the management of the neck in esthesioneuroblastoma continues to be a significant challenge in the treatment algorithm of these complex patients.

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 2000 Sep;22(6):550-8 [10941155.001]
  • [Cites] Lancet Oncol. 2001 Nov;2(11):683-90 [11902539.001]
  • [Cites] Head Neck. 2011 Oct;33(10):1520-9 [20737485.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):443-9 [20421144.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2010;72(2):113-8 [20453548.001]
  • [Cites] Rhinol Suppl. 2010;(22):1-143 [20502772.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2009 Oct;135(10):1030-4 [19841344.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2009 Sep;266(9):1333-52 [19597837.001]
  • [Cites] Laryngoscope. 2009 Jul;119(7):1412-6 [19444891.001]
  • [Cites] Oral Oncol. 2009 Apr-May;45(4-5):402-8 [19375379.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Sep;29(8):1561-3 [18499797.001]
  • [Cites] J Surg Oncol. 2008 Jun 15;97(8):658-64 [18493946.001]
  • [Cites] Acta Otolaryngol. 2002 Mar;122(2):215-21 [11936917.001]
  • [Cites] Laryngoscope. 2003 Mar;113(3):502-7 [12616204.001]
  • [Cites] Head Neck. 2003 Jul;25(7):529-34 [12808655.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2003 Apr;11(2):112-8 [14515089.001]
  • [Cites] Laryngoscope. 2003 Nov;113(11):1935-8 [14603051.001]
  • [Cites] Head Neck. 1992 Nov-Dec;14(6):477-82 [1468921.001]
  • [Cites] J Laryngol Otol. 1998 Jul;112(7):628-33 [9775291.001]
  • [Cites] Acta Neurochir (Wien). 2005 Jun;147(6):595-601; discussion 601-2 [15806328.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 Feb;132(2):134-8 [16490869.001]
  • (PMID = 20706843.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] ENG
  • [Grant] United States / NIDCD NIH HHS / DC / DC005360-07; United States / NIDCD NIH HHS / DC / T32 DC005360; United States / NIDCD NIH HHS / DC / T32 DC005360-07
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Other-IDs] NLM/ NIHMS255289; NLM/ PMC3005584
  •  go-up   go-down


8. Tokiya R, Imajo Y, Yoden E, Hiratsuka J, Kobatake M, Gyoten M, Imai S, Kajihara Y: A long-term survivor of leiomyosarcoma around the right side of the base of the skull: effective radiotherapy combined with intra-arterial chemotherapy. Int J Clin Oncol; 2002 Feb;7(1):57-61
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A long-term survivor of leiomyosarcoma around the right side of the base of the skull: effective radiotherapy combined with intra-arterial chemotherapy.
  • We report a rare case of a leiomyosarcoma that developed around the right side of the base of the skull in a 51-year-old woman.
  • A leiomyosarcoma, originating around the right side of the neck and base of the skull was diagnosed.
  • Curative resection of the leiomyosarcoma around the right side of the base of the skull was not possible.
  • Therefore, external beam radiotherapy (EBRT) combined with intra-arterial chemotherapy and hyperthermia was employed.
  • After the treatment, the tumor decreased in size to 45% of its initial volume, and, simultaneously, her symptoms completely disappeared.
  • The patient initially remained clinically free of the disease, but showed reaggravations at the primary tumor site 3 years and 3 months, and 4 years and 11 months, after the first treatment.
  • The reaggravations were treated with EBRT combined with intra-arterial chemotherapy.
  • As a result, she survived for 5 years and 7 months after the first treatment.
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Leiomyosarcoma / diagnosis. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis. Survivors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11942051.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


9. Jian JJ, Cheng SH, Tsai SY, Yen KC, Chu NM, Chan KY, Tan TD, Cheng JC, Lin YC, Leu SY, Hsieh CI, Tsou MH, Lin CY, Huang AT: Improvement of local control of T3 and T4 nasopharyngeal carcinoma by hyperfractionated radiotherapy and concomitant chemotherapy. Int J Radiat Oncol Biol Phys; 2002 Jun 1;53(2):344-52
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement of local control of T3 and T4 nasopharyngeal carcinoma by hyperfractionated radiotherapy and concomitant chemotherapy.
  • PURPOSE: When the primary tumor of nasopharyngeal carcinoma (NPC) is treated at the base of skull and intracranium with conventional radiotherapy, the result is generally poor.
  • In this report, we investigated whether hyperfractionated radiotherapy (HFRT) and concomitant chemotherapy (CCT) could achieve better local control and survival in NPC patients with T3 and T4 lesions.
  • HFRT was administered at 1.2 Gy per fraction, two fractions per day, Monday-Friday for 62 fractions for a total dose of 74.4 Gy.
  • Concomitant chemotherapy consisting of cis-diamino-dichloroplatinum (CDDP) alone or CDDP and 5-fluorouracil was delivered simultaneously with radiotherapy during Weeks 1 and 6.
  • Adjuvant chemotherapy consisted of CDDP and 5-fluorouracil for 2 to 3 cycles and was given monthly beginning 1 month after completion of radiation.
  • Most patients tolerated the combined modality treatments relatively well; 88% of patients completed their radiation treatment within 8 weeks.
  • The treatment-related toxicity was acceptable and reversible.
  • We would recommend using HFRT with CCT for advanced T-stage NPC if the three-dimensional conformal radiation planning shows a significant portion of the brainstem to be inside the treatment field.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Dose Fractionation. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Mouth Mucosa. Neoplasm Metastasis. Neoplasm Staging. Patient Compliance. Stomatitis / etiology. Survival Rate. Weight Loss

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12023138.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Aida Y, Igarashi A, Inoue S, Abe S, Shibata Y, Kubota I: [A case of lung adenocarcinoma exhibiting Garcin syndrome]. Nihon Kokyuki Gakkai Zasshi; 2010 Jan;48(1):66-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a rare case of lung adenocarcinoma exhibiting Garcin syndrome due to skull base metastasis.
  • A diagnosis of lung adenocarcinoma and intraperitoneal lymph node metastases was given to a 50-year-old man after pathological examination of a superclavicular lymph node biopsy.
  • After systemic chemotherapy with cisplatin plus docetaxel, he had left hearing loss and vertigo.
  • Since auditory nerve damage might occur due to cisplatin, the chemotherapy regimen was changed.
  • He was diagnosed with Garcin syndrome due to the skull base and spinal cord metastases by brain and spine MRI, and cytological examination of the spinal fluid.
  • [MeSH-minor] Humans. Male. Middle Aged. Skull Base Neoplasms / secondary. Spinal Cord Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20163025.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Kalcioğlu MT, Oncel S, Miman MC, Erdem T, Mizrak B: A case of Ewing's sarcoma in the mandible and the skull base. Kulak Burun Bogaz Ihtis Derg; 2003 Nov;11(5):144-7
Genetic Alliance. consumer health - Ewing's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of Ewing's sarcoma in the mandible and the skull base.
  • The treatment was considerably delayed because of the initial diagnostic difficulties due to its insidious presentation and the unwillingness of the child's parents to further investigations and treatment.
  • Cranial computed tomography and magnetic resonance imaging with contrast showed a destructive lesion extensively involving the right mandible and the skull base, with invasion to the intracranial space.
  • Histologic and immunohistochemical findings were consistent with the diagnosis of Ewing's sarcoma.
  • The patient received systemic chemotherapy and radiotherapy following surgery.
  • A month after radiation therapy, radiologic investigations showed a lung mass suggestive of metastasis.
  • [MeSH-major] Mandibular Neoplasms / diagnosis. Sarcoma, Ewing / diagnosis. Skull Base Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Combined Modality Therapy. Diagnosis, Differential. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15542942.001).
  • [ISSN] 1300-7475
  • [Journal-full-title] Kulak burun boğaz ihtisas dergisi : KBB = Journal of ear, nose, and throat
  • [ISO-abbreviation] Kulak Burun Bogaz Ihtis Derg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


12. Lu TX, Mai WY, Teh BS, Hu YH, Lu HH, Chiu JK, Carpenter LS, Woo SY, Butler EB: Important prognostic factors in patients with skull base erosion from nasopharyngeal carcinoma after radiotherapy. Int J Radiat Oncol Biol Phys; 2001 Nov 1;51(3):589-98
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Important prognostic factors in patients with skull base erosion from nasopharyngeal carcinoma after radiotherapy.
  • PURPOSE: To evaluate the long-term outcome and prognostic factors in patients with skull base erosion from nasopharyngeal carcinoma after initial radiotherapy (RT).
  • METHODS AND MATERIALS: From January 1985 to December 1986, 100 patients (71 males, 29 females) with a diagnosis of nasopharyngeal carcinoma were found on computed tomography (CT) to have skull base erosion.
  • Ninety-six patients had World Health Organization type III undifferentiated carcinoma, and 4 had type I.
  • All patients underwent external beam RT (EBRT) alone to 66-80 Gy during 6-8 weeks.
  • A daily fraction size of 2 Gy was delivered using 60Co or a linear accelerator.
  • No patient received chemotherapy.
  • A difference in the time course of local recurrence and distant metastasis was observed.
  • Both local recurrence and distant metastasis often occurred within the first 2 years after RT.
  • The causes of death included local recurrence (n = 59), distant metastasis (n = 21), both local recurrence and distant metastasis (n = 1), and unrelated causes (n = 5).
  • CONCLUSIONS: We present one of the longest follow-ups of patients with nasopharyngeal carcinoma invading the skull base.
  • A subgroup of patients with skull base involvement had long-term survival after RT alone.
  • [MeSH-major] Nasopharyngeal Neoplasms / pathology. Nasopharyngeal Neoplasms / radiotherapy. Skull Base Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Analysis of Variance. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / mortality. Neoplasm Staging. Prognosis. Proportional Hazards Models. Skull Base / pathology. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11597797.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Fassett DR, Couldwell WT: Metastases to the pituitary gland. Neurosurg Focus; 2004 Apr 15;16(4):E8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Differentiation of pituitary metastasis from other pituitary tumors based on neuroimaging alone can be difficult, although certain features, such as thickening of the pituitary stalk, invasion of the cavernous sinus, and sclerosis of the surrounding sella turcica, can indicate metastasis to the pituitary gland.
  • Differentiating metastasis to the pituitary gland from bone metastasis to the skull base, which invades the sella turcica, can also be difficult.
  • In metastasis to the pituitary gland, surrounding sclerosis in the sella turcica is usually minimal compared with metastasis to the skull base.
  • Treatment for these tumors is often multimodal and includes surgery, radiation therapy, and chemotherapy.
  • [MeSH-major] Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / secondary
  • [MeSH-minor] Combined Modality Therapy. Diagnostic Imaging / methods. Humans. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15191337.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


14. Watanabe Y, Itoh S, Mitsuhata N: [Multidisciplinary treatment for advanced bladder cancer--a case report]. Gan To Kagaku Ryoho; 2004 May;31(5):793-6
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multidisciplinary treatment for advanced bladder cancer--a case report].
  • The patient was a 63-year-old woman who had been diagnosed with advanced bladder cancer with renal dysfunction and bilateral bulky pulmonary metastasis.
  • Following surgery, she received intermittent intra-arterial (IA) low-dose CDDP chemotherapy via the infusion port and concurrent bronchial arterial infusion and radiation (40 Gy for the left lung).
  • Repeated IA chemotherapy was discontinued from June 2001 because of neurological symptoms.
  • In September 2001, a left skull base metastasis was detected and was treated by radiation 40 Gy.
  • In November 2002, a left patella metastasis appeared and was treated by IA chemotherapy with angiotensin II and radiation 30 Gy.
  • We confirmed that multidisciplinary treatment contributed to her approximately 3-year survival with good QOL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / radiotherapy. Doxorubicin / analogs & derivatives. Infusion Pumps, Implantable. Lymph Nodes / pathology. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / radiotherapy
  • [MeSH-minor] Bone Neoplasms / secondary. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Infusions, Intra-Arterial. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Quality of Life. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15170995.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin; D58G680W0G / pirarubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


15. Massot-Punyet R, Almajano J, Camacho JM: [Cerebral metastasis]. Rev Neurol; 2000 Dec 16-31;31(12):1242-7
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cerebral metastasis].
  • INTRODUCTION: Cancer and its metastatic complications are one of the most important types of disease due to their high morbidity and mortality (nearly 100%).
  • Cancer of the lung and breast are the main causes of CM, whilst cancer of the prostate metastasizes more to the base of the skull and spinal coverings.
  • In spite of surgery, radiotherapy and chemotherapy the average survival with CM is three months.
  • CONCLUSIONS: CM is a diagnosis which should be considered in patients of middle age or older.
  • [MeSH-minor] Adult. Breast Neoplasms / pathology. Carcinoma / pathology. Carcinoma / secondary. Child. Diagnostic Imaging. Epilepsy / etiology. Female. Humans. Lung Neoplasms / pathology. Male. Melanoma / pathology. Melanoma / secondary. Organ Specificity. Palliative Care. Papilledema / etiology. Prognosis. Prostatic Neoplasms / pathology. Skull Base Neoplasms / secondary. Spain / epidemiology. Spinal Cord Neoplasms / secondary. Vision Disorders / etiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11205567.001).
  • [ISSN] 0210-0010
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Multicenter Study; Review
  • [Publication-country] Spain
  • [Number-of-references] 16
  •  go-up   go-down


16. Muto E, Shioyama Y, Nakamura K, Ohga' S, Nomoto S, Toba T, Yoshitake T, Soeda H, Terashima H, Honda H: Adult rhabdomyosarcoma in the nasal and paranasal sinuses showing complete local response to a combination of chemotherapy and radiotherapy using 3D-CRT and IMRT. Fukuoka Igaku Zasshi; 2005 Oct;96(10):363-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult rhabdomyosarcoma in the nasal and paranasal sinuses showing complete local response to a combination of chemotherapy and radiotherapy using 3D-CRT and IMRT.
  • Computed tomography (CT) revealed a large tumor in the nasal and left paranasal sinuses invading the left orbital cavity and anterior skull base, and lymph node swellings in the submental and left accessory nerve areas.
  • A biopsy specimen from the nasal tumor was diagnosed histologically as a rhabdomyosarcoma, alveolar type.
  • Radiotherapy with a total dose of 60 Gy was carried out to control the primary disease.
  • Combined with radiotherapy, chemotherapy was also performed for the treatment of lymph-node metastases and distant diseases.
  • After the treatment was completed, the primary tumor and lymph-node metastases disappeared completely; there was no sign of re-growth during the follow-up period.
  • Chemoradiotherapy may be an effective treatment also for inoperable adult rhabdomyosarcoma in the head and neck region.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Paranasal Sinus Neoplasms / therapy. Radiotherapy, Conformal / methods. Radiotherapy, Intensity-Modulated / methods. Rhabdomyosarcoma / therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Fatal Outcome. Female. Humans. Lymphatic Metastasis. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16408493.001).
  • [ISSN] 0016-254X
  • [Journal-full-title] Fukuoka igaku zasshi = Hukuoka acta medica
  • [ISO-abbreviation] Fukuoka Igaku Zasshi
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VAC protocol
  •  go-up   go-down


17. Gunn GB, Villa RD, Sedler RR, Hardwicke F, Fornari GA, Mark RJ: Nasopharyngeal carcinoma metastasis to the pituitary gland: a case report and literature review. J Neurooncol; 2004 May;68(1):87-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasopharyngeal carcinoma metastasis to the pituitary gland: a case report and literature review.
  • While nasopharyngeal carcinoma (NPC) commonly invades the skull base, true central nervous system metastasis is a rare phenomenon.
  • We report a case of NPC metastasis to the pituitary gland and review the literature for similar events.
  • Eight months after his definitive radiation therapy, our patient presented with symptoms of optic chiasm compression and panhypopituitarism.
  • Medical imaging revealed a pituitary mass but demonstrated no evidence of skull base erosion or direct intracranial extension.
  • The patient was treated with high dose chemotherapy followed by autologous stem cell transplant, which produced short-term symptomatic relief and at least a 7 month survival.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Epstein-Barr Virus Infections / pathology. Epstein-Barr Virus Infections / therapy. Herpesvirus 4, Human / isolation & purification. Humans. In Situ Hybridization. Male. Middle Aged. RNA Probes. RNA, Viral / genetics. RNA, Viral / metabolism. Stem Cell Transplantation. Transplantation, Autologous

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 2001 Sep;23(9):799-803 [11505492.001]
  • [Cites] Am J Otolaryngol. 2000 Mar-Apr;21(2):80-4 [10758991.001]
  • [Cites] Oncology. 1973;27(6):533-42 [4355105.001]
  • [Cites] Chang Gung Med J. 2000 Feb;23 (2):118-22 [10835808.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):231-6 [8625228.001]
  • [Cites] J Neurooncol. 1994;22(3):227-30 [7760099.001]
  • [Cites] J Neurosurg. 1998 Jul;89(1):69-73 [9647174.001]
  • [Cites] Clin Radiol. 1978 Jan;29(1):27-30 [624198.001]
  • [Cites] J Clin Oncol. 1993 Dec;11(12 ):2434-42 [8246032.001]
  • [Cites] Eur Neurol. 1974;11(5):317-22 [4852541.001]
  • [Cites] Strahlenther Onkol. 2003 Feb;179(2):123-8 [12590324.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 1995 Feb;55(2):195-8 [7750063.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):398-405 [11905411.001]
  • [Cites] J Laryngol Otol. 1991 Sep;105(9):772-3 [1919352.001]
  • (PMID = 15174525.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA Probes; 0 / RNA, Viral
  •  go-up   go-down


18. Abada RL, Kadiri F, Tawfik N, Benchakroun N, Bouchbika Z, Chekkoury AI, Benchakroun Y, Benider A: [Multiple metastases of a mandibular ameloblastoma]. Rev Stomatol Chir Maxillofac; 2005 Jun;106(3):177-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBSERVATION: A 50-year-old woman presented a jugal metastasis of a mandibular ameloblastom which had been treated several times 28 years earlier.
  • Six months after resection of the metastasis, the patient developed multiple cervical node metastases which were removed by radical curettage.
  • Five months later, new metastases developed on the scalp and three months later a voluminous metastasis involving the right hemiface extended to the base of the skull.
  • The time to development of a metastasis is generally very long and metastases usually remain asymptomatic.
  • Several factors predictive of metastasis have been described: female gender, age at onset of primary tumor (2nd to 3rd decade) and multiple local recurrences.
  • There is no standard treatment for metastases.
  • Chemotherapy is not effective.
  • Surgical resection remains the treatment of choice.
  • [MeSH-minor] Female. Follow-Up Studies. Head and Neck Neoplasms / secondary. Humans. Lymphatic Metastasis / pathology. Middle Aged. Paranasal Sinus Neoplasms / secondary. Scalp / pathology. Skin Neoplasms / secondary. Skull Neoplasms / secondary. Zygoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15976707.001).
  • [ISSN] 0035-1768
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


19. Cheng SH, Tsai SY, Yen KL, Jian JJ, Feng AC, Chan KY, Hong CF, Chu NM, Lin YC, Lin CY, Tan TD, Hsieh CY, Chong V, Huang AT: Prognostic significance of parapharyngeal space venous plexus and marrow involvement: potential landmarks of dissemination for stage I-III nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys; 2005 Feb 1;61(2):456-65
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To determine whether the parapharyngeal space venous plexus and marrow of the skull base bones are anatomic landmarks of the potential routes for the spread of disease for Stage I-III (American Joint Commission on Cancer 1997 staging system) nasopharyngeal carcinoma (NPC).
  • Patients who had undergone inadequate radiotherapy at a dose of <60 Gy and/or preradiotherapy chemotherapy before the imaging evaluation were excluded from the study.
  • The 5-year distant metastasis-free survival rate, with and without adjuvant chemotherapy, was 97% and 96%, respectively.
  • Their 5-year recurrence-free survival rate, with and without adjuvant chemotherapy, was 76.8% and 53.2% (p = 0.01), respectively.
  • CONCLUSION: Our findings suggest that the risk of distant metastasis in Stage I-III NPC patients without parapharyngeal space extension or T3 disease is extremely low.
  • Invasion into the parapharyngeal space venous plexus and marrow of the skull base bones is associated with distant metastasis, and involvement of these anatomic sites is considered a potential route for hematogenous disease spread in patients with Stage I-III NPC.
  • [MeSH-major] Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis / prevention & control. Neoplasm Staging. Pharynx. Practice Guidelines as Topic. Prognosis. Proportional Hazards Models. Survival Rate. Treatment Failure

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667967.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


20. Pallini R, Sabatino G, Doglietto F, Lauretti L, Fernandez E, Maira G: Clivus metastases: report of seven patients and literature review. Acta Neurochir (Wien); 2009 Apr;151(4):291-6; discussion 296

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Tumours of the clivus are rare and metastases involving this area have been previously described only as single case reports or included in series with other skull base tumours.
  • FINDINGS: Of 46 patients who underwent surgery for clivus bone tumours, seven proved to harbour a metastasis.
  • This figure represents 0.18% and 0.42% respectively of intracranial and skull base tumours which were treated in our Institution in the study period.
  • In spite of radiotherapy and chemotherapy, the mean survival was 12 months.
  • CONCLUSION: Though exceedingly rare, metastases involving the clivus should be considered in the differential diagnosis with clivus chordoma.
  • The trans-sphenoidal approach is the ideal procedure to establish a histopathological diagnosis.
  • [MeSH-major] Carcinoma / secondary. Cranial Fossa, Posterior / pathology. Skull Base Neoplasms / secondary
  • [MeSH-minor] Abducens Nerve Diseases / etiology. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Liver Neoplasms / pathology. Lung Neoplasms / pathology. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Prostatic Neoplasms / pathology. Skin Neoplasms / pathology. Survival Rate. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19259614.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 30
  •  go-up   go-down


21. Lee CC, Chu ST, Chou P, Lee CC, Chen LF: The prognostic influence of prevertebral space involvement in nasopharyngeal carcinoma. Clin Otolaryngol; 2008 Oct;33(5):442-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The purpose of this study was to evaluate the effect of prevetebral space involvement on treatment outcomes in patients with nasopharyngeal carcinoma (NPC) who were treated with radiotherapy/concurrent chemoradiotherpy or concurrent chemoradiotherpy with adjuvant chemotherapy.
  • Thirty-nine patients were excluded because of the presence of distant metastasis at the time of presentation, loss of follow-up and incomplete image information.
  • Pearson's chi-square and Fisher's exact test were also used to evaluate the correlation between failure patterns and treatment modality.
  • Patients with prevertebral space involvement conferred a poor overall survival rate and metastasis-free survival rate compared with those without prevertebral space invasion (P = 0.04 and 0.02 respectively).
  • Multivariate analysis showed that prevertebral space invasion was associated with an increased risk for distant metastasis [hazard ratio (HR) 14, 95% confidence interval (CI) 1.0-17.4; P = 0.03)] and overall survival (HR 7, 95% CI 1.1-135; P = 0.04).
  • In patients with prevertebral space involvement, their metastasis-free survival rate, with and without adjuvant chemotherapy, was 100% and 72.7% (P = 0.047).
  • Nasopharyngeal carcinoma patients with prevertebral space involvement have more recurrence and poorer survival rates and should be the group to benefit from concurrent chemoradiotherapy followed by adjuvant chemotherapy.
  • [MeSH-minor] Adipose Tissue / pathology. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain / pathology. Cervical Vertebrae / pathology. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Oropharynx / pathology. Prognosis. Retrospective Studies. Skull Base / pathology. Young Adult

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18983377.001).
  • [ISSN] 1749-4486
  • [Journal-full-title] Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery
  • [ISO-abbreviation] Clin Otolaryngol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


22. Sampath P, Park MC, Huang D, Deville C, Cortez S, Chougule P: Esthesioneuroblastoma (olfactory neuroblastoma) with hemorrhage: an unusual presentation. Skull Base; 2006 Aug;16(3):169-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Its biological activity ranges from indolent growth to local recurrence and rapid widespread metastasis.
  • Treatment options consist of surgical resection followed by radiation therapy for primary lesions and the addition of chemotherapy for advanced, recurrent, or metastatic lesions.
  • Imaging showed a large frontal skull-based tumor associated with intratumoral hemorrhage.
  • Postoperatively, she received adjuvant intensity-modulated radiation therapy and chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1999 Oct;109(10):1539-43 [10522919.001]
  • [Cites] Head Neck. 2000 Sep;22(6):550-8 [10941155.001]
  • [Cites] Neurosurg Clin N Am. 2000 Oct;11(4):693-701 [11082179.001]
  • [Cites] Lancet Oncol. 2001 Nov;2(11):683-90 [11902539.001]
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2003 Apr;11(2):112-8 [14515089.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Nov;129(11):1186-92 [14623748.001]
  • [Cites] Laryngoscope. 1992 Aug;102(8):843-9 [1495347.001]
  • [Cites] Otolaryngol Head Neck Surg. 2004 May;130(5):567-74 [15138422.001]
  • [Cites] Laryngoscope. 1990 Oct;100(10 Pt 1):1052-8 [2215035.001]
  • [Cites] Cancer. 1989 Jun 15;63(12):2426-8 [2720589.001]
  • [Cites] Cancer. 1979 Sep;44(3):1087-94 [383268.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1977 Nov-Dec;86(6 Pt 1):760-5 [596773.001]
  • [Cites] Head Neck. 1995 Mar-Apr;17(2):114-8 [7558807.001]
  • [Cites] J Neurooncol. 1995 Oct;26(1):35-43 [8583243.001]
  • [Cites] Anticancer Res. 1997 Jul-Aug;17(4A):2683-706 [9252701.001]
  • [Cites] Ear Nose Throat J. 1998 Nov;77(11):890-1 [9846465.001]
  • (PMID = 17268590.001).
  • [ISSN] 1531-5010
  • [Journal-full-title] Skull base : official journal of North American Skull Base Society ... [et al.]
  • [ISO-abbreviation] Skull Base
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1586171
  •  go-up   go-down


23. Mohammadinezhad C: Chondrosarcoma of the jaw. J Craniofac Surg; 2009 Nov;20(6):2097-100
Genetic Alliance. consumer health - Chondrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, molecular and genomic studies thought to be useful tools in a more definite diagnosis, accurate treatment, and quality of life of patients.
  • The most acceptable choice of treatment of the chondrosarcoma is wide resection.
  • Radiotherapy and chemotherapy as an adjunctive or palliative treatment remain controversial.
  • However, lifelong follow-up is essential because chondrosarcoma shows a high incidence of local recurrence as well as regional and distant metastasis more than 2 decades later.
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Nose. Orbital Implants. Prostheses and Implants. Skull Base Neoplasms / secondary. Skull Base Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19881362.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Majumder A, Devi HP, Singh TI: Unusual clinical presentation of nasopharyngeal carcinoma--report of 3 cases. J Indian Med Assoc; 2008 Jan;106(1):46, 48, 52
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among head and neck cancers, nasopharyngeal carcinoma has the poorest prognosis because of the primary site's proximity to the base of the skull and multiple vital structures.
  • Here in this series, 3 patients were presented, one with distant metastasis, one with upper airway obstruction and another with complete visual loss and difficulty in swallowing.
  • They all were treated with combination chemotherapy and external beam radiation.
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Endoscopy. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705270.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


25. Aribas BK, Cetindag F, Ozdogan Z, Dizman A, Demir P, Unlu DN, Yologlu Z: Nasopharyngeal carcinomas: prognostic factors and treatment features. J Egypt Natl Canc Inst; 2008 Sep;20(3):230-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasopharyngeal carcinomas: prognostic factors and treatment features.
  • All imaging data including CT and MRI were reevaluated according to the criteria which determine parapharyngeal, oropharyngeal, nasal, skull-base (bone)/sinus, infratemporal fossa, orbit, intracranial involvements and lymph node metastasis by our radiologists.
  • The patients were restaged using the AJCC 2002 classification with these new radiological findings and clinical data base.
  • Gender, age (40-year cut-off), histology, T- and N-stage, tumor size, regional involvement, radiotherapy and/or chemotherapy and response to therapy were studied as variables.
  • We found that age, gender, WHO type, radiotherapy and/or chemotherapy, N-stage and response to therapy were significant prognostic factors on disease-free survival and overall survival.
  • In the chemo-radiotherapy group, we did not detect any survival difference between patients given four or fewer chemotherapy courses.
  • CONCLUSIONS: Radiotherapy improved survival but chemotherapy, in the neoadjuvant and adjuvant setting, had no added effect to radiotherapy.
  • N-stage and response to treatment were the most important independent predictors on survival.
  • Age, gender, type, therapy and bone/sinus involvement were among the predictive factors on multivariate analysis, as well.
  • KEY WORDS: Nasopharyngeal carcinoma - Prognostic factor - MRI - CT - Radiotherapy - Chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20424653.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


26. Güneş M, Günaldi O, Tuğcu B, Tanriverdi O, Güler AK, Cöllüoğlu B: Intracranial chondrosarcoma: a case report and review of the literature. Minim Invasive Neurosurg; 2009 Oct;52(5-6):238-41
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for intracranial chondrosarcoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Chondrosarcoma is a rare malignant tumor originating from cartilagenous tissue.
  • Skull radiography revealed a radioopaque lesion in the right parieto-occipital region.
  • Cranial computed tomography and magnetic resonance imaging showed a mass lesion including calcification areas and homogenous contrast enhancement in the right parieto-occipital region.
  • A classical type chondrosarcoma was confirmed histopathologically.
  • Most of them are located at the skull base.
  • Meningiomas, solitary fibrous tumor, chordoma, hemangiopericytoma, metastasis and vascular malformations should be considered as differential diagnoses.
  • Radical surgical removal of the tumor is the preferred management procedure.
  • Chemotherapy and radiotherapy may by added as adjuvant therapy.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / surgery. Chondrosarcoma / diagnosis. Chondrosarcoma / surgery
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male. Microsurgery. Neurosurgical Procedures. Prognosis. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20077365.001).
  • [ISSN] 1439-2291
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 26
  •  go-up   go-down


27. Issing WJ, Taleban B, Tauber S: [Diagnosis and management of squamous cell carcinoma of the head and neck region with unknown primary. A survey of 167 patients]. Laryngorhinootologie; 2003 Sep;82(9):659-65
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and management of squamous cell carcinoma of the head and neck region with unknown primary. A survey of 167 patients].
  • [Transliterated title] Diagnose und Management von Plattenepithelkarzinomen mit unbekanntem Primärtumor im Kopf-Hals-Bereich.
  • BACKGROUND: Carcinoma of unknown primary is defined as histological diagnosis of metastasis without diagnosis of a primary tumor.
  • Histological examination of CUP-metastasis of the neck most frequently shows a squamous cell carcinoma.
  • Primary radiotherapy was the treatment of choice in 28 patients, 8 patients received combined radio-chemotherapy as primary treatment and 7 patients were treated with chemotherapy alone.
  • No treatment was performed in 6 patients.
  • RESULTS: By comparing the treatment methods there was a significant difference of patient survival in regard to the treatment.
  • Patients treated according to treatment-plan II, which includes an additional "diagnostic" tonsillectomy, is significantly higher than that of patients simply undergoing neck dissection and postoperative radiotherapy or primary radiotherapy alone.
  • Treatment of choice in patients with cervical CUP should be a surgical procedure including radical neck dissection and diagnostic bilateral tonsillectomy followed by postoperative radiation of the cervical lymph drainage.
  • Additional postoperative radiation of the pharynx from the base of the skull to the upper oesophagus should also be considered, in order to treat a possible--small--primary tumor in this region.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neck Dissection. Retrospective Studies. Survival Analysis. Time Factors. Tonsillar Neoplasms / surgery. Tonsillectomy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Diagnosis Unknown.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14517763.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


28. Lin PY, Chen WM, Hsieh YL, Chen WY, Chen TH: Orbital metastatic osteosarcoma. J Chin Med Assoc; 2005 Jun;68(6):286-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 15-year-old girl with right tibial osteosarcoma, diagnosed 22 months previously, developed right orbital and skull base metastases, with symptoms including painful protrusion of the right eyeball and severe visual impairment.
  • She underwent embolization of the metastatic tumor, local irradiation, and chemotherapy followed by intralesional resection of the mass because extensive involvement of the skull base precluded complete surgical resection.
  • After 24 months of follow-up from the presentation of orbital metastasis, the patient's right-eye vision remained unchanged.
  • In conclusion, orbital metastasis of osteosarcoma is rare, but may lead to severe visual impairment.
  • Combined radiotherapy, chemotherapy and surgery can partially relieve symptoms, but cannot completely eradicate the tumors.
  • [MeSH-minor] Adolescent. Combined Modality Therapy. Female. Humans. Visual Acuity

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15984825.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


29. Zhang LW, Zhang MS, Qi J, Zhang JT, Li GL, Luo L, Wang ZC: Management of intracranial invasive olfactory neuroblastoma. Chin Med J (Engl); 2007 Feb 5;120(3):224-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to investigate the clinical characteristics and treatments of intracranial invasive ONB.
  • Their clinical features, radiological and pathological characteristics, and surgical treatments were analyzed.
  • Among the 5 patients, 1 received transnasal biopsy, and 4 were operated through the transfrontal or extended bifrontal approaches to reconstruct the skull base.
  • After the operation, all the patients received radiotherapy, and one received chemotherapy.
  • Two patients had metastasis into the lumbosacral spinal canal 6 and 8 months after the operation, one of them received a second operation and the other died.
  • [MeSH-minor] Adolescent. Adult. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17355826.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


30. Gil Z, Fliss DM: Contemporary management of head and neck cancers. Isr Med Assoc J; 2009 May;11(5):296-300
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HNCs can originate in the skin or soft tissue, in the upper aerodigestive tracts (oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, paranasal sinuses, salivary glands), or in the thyroid.
  • In each of these sites, tumors vary not only by the primary site but also by pathophysiology, biological behavior, and sensitivity to radiotherapy or chemotherapy.
  • The main goals of therapy are ablation of the cancer while minimizing morbidity and preserving function and cosmesis.
  • Early-stage HNC (stage I and II) should be managed with a single modality, and advanced tumors (stage III and IV) with multimodality therapy.
  • Treatment should be directed to the primary tumor and the area of its lymphatic drainage--the neck lymph nodes.
  • [MeSH-major] Head and Neck Neoplasms / therapy
  • [MeSH-minor] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Laryngeal Neoplasms / diagnosis. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / therapy. Lymphatic Metastasis. Neck Dissection. Prognosis. Quality of Life. Radiotherapy, Adjuvant. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19637508.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Israel
  • [Number-of-references] 29
  •  go-up   go-down


31. Li Y, Zhang TM, An YZ, Shi JT, Fu JD, Qiu E: [Clinical study of lacrimal gland tumor involving anterior and middle cranial fossae]. Zhonghua Yi Xue Za Zhi; 2006 Jun 20;86(23):1597-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the clinical manifestations of lacrimal gland tumor involving the anterior and middle cranial fossae and the effect of transcranial-orbital approach in treatment of such tumor.
  • Recurrence of tumor occurred in 4 cases, and 1 case died from distant metastasis of adenocarcinoma.
  • Suitable treatment strategy should by combination of operation with irradiation or chemotherapy.
  • [MeSH-major] Eye Neoplasms / pathology. Lacrimal Apparatus / pathology. Skull Base Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16854296.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


32. Noël G, Dessard-Diana B, Vignot S, Mazeron JJ: [Treatment of nasopharyngeal cancer: literature review]. Cancer Radiother; 2002 Apr;6(2):59-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of nasopharyngeal cancer: literature review].
  • [Transliterated title] Les traitements des cancers du nasopharynx: revue de la littérature.
  • The conventional radiotherapy and the associated treatments improved the prognostic of nasopharyngeal cancer.
  • A better selection of the patients who must have a more aggressive treatment also probably contributed to this improvement.
  • The patients with a locally advanced tumor, with or not an invasion of the base of the skull and/or neurological symptoms, must have an aggressive locally treatment.
  • Dose within the tumor must be at least 70 Gy and the prophylactic nodal dose, at least 50 Gy.
  • Association with chemotherapy allowed, on the other hand, an improvement of the prognostic locally advanced cancers.
  • Neoadjuvant or adjuvant chemotherapy was largely used to attempt to limit the risks of systemic dissemination, but an improvement of results was not clearly demonstrated.
  • Salvage treatments are, however, disappointing for when distant relapse occurs which suggests a difference in chemosensitivity between primary tumor and metastasis.
  • [MeSH-major] Nasopharyngeal Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Prognosis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12035485.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 186
  •  go-up   go-down


33. Barrera JL, Verastegui E, Meneses A, Zinser J, de la Garza J, Hadden JW: Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial. Arch Otolaryngol Head Neck Surg; 2000 Mar;126(3):345-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To test the efficacy of a natural cytokine mixture (IRX-2), cyclophosphamide, indomethacin, and zinc to induce immune regression of squamous cell carcinoma (SCC) of the head and neck (H&N) prior to conventional therapy and to characterize the responses.
  • The patients were treated with 20 days of perilymphatic injections of IRX-2 (administered subcutaneously at the base of the skull) in combination with contrasuppression consisting of a low-dose infusion of cyclophosphamide (300 mg/m2), and daily oral indomethacin and zinc (StressTabs) in a 21-day cycle before surgery and/or radiotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Cytokines / therapeutic use. Head and Neck Neoplasms / therapy. Immunotherapy / methods. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Disease-Free Survival. Drug Combinations. Female. Humans. Indomethacin / adverse effects. Indomethacin / therapeutic use. Lymphatic Metastasis. Lymphocyte Activation / drug effects. Lymphocyte Activation / immunology. Male. Middle Aged. Neoplasm Staging. Zinc / adverse effects. Zinc / therapeutic use

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. INDOMETHACIN .
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10722007.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Cytokines; 0 / Drug Combinations; 0 / IRX 2; 8N3DW7272P / Cyclophosphamide; J41CSQ7QDS / Zinc; XXE1CET956 / Indomethacin
  •  go-up   go-down


34. Katz TS, Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Villaret DB: Malignant tumors of the nasal cavity and paranasal sinuses. Head Neck; 2002 Sep;24(9):821-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the role of radiation therapy in patients with nasal cavity and paranasal sinus tumors.
  • MATERIALS AND METHODS: Between October 1964 and July 1998, 78 patients with malignant tumors of the nasal cavity (48 patients), ethmoid sinus (24 patients), sphenoid sinus (5 patients), or frontal sinus (1 patient) were treated with curative intent by radiation therapy alone or in the adjuvant setting.
  • Forty-seven patients were treated with irradiation alone, 25 with surgery and postoperative irradiation, 2 with preoperative irradiation and surgery, and 4 with chemotherapy in combination with irradiation with or without surgery.
  • RESULTS: The 5-year actuarial local control rate for stage I (limited to the site of origin; 22 patients) was 86%; for stage II (extension to adjacent sites (eg, adjacent sinuses, orbit, pterygomaxillary fossa, nasopharynx; 21 patients) was 65%; and for stage III (destruction of skull base or pterygoid plates, or intracranial extension; 35 patients) was 34%.
  • Of the 67 (86%) patients who were initially seen with node-negative disease, 39 (58%) received no elective neck treatment, and 28 (42%) received elective neck irradiation.
  • Of the 39 patients who received no elective neck treatment, 33 (85%) did not experience recurrence in the neck compared with 25 (89%) of 28 patients who received elective neck irradiation.
  • CONCLUSION: Surgery and postoperative radiation therapy may result in improved local control, absolute survival, and complications when compared with radiation therapy alone.
  • [MeSH-major] Carcinoma / therapy. Nasal Cavity. Nose Neoplasms / therapy. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blindness / etiology. Blindness / prevention & control. Cause of Death. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Neoplasm Staging. Osteoradionecrosis / etiology. Postoperative Care. Preoperative Care. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Risk Factors. Survival Rate. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley Periodicals, Inc. Head Neck 24: 821-829, 2002
  • (PMID = 12211046.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Issing PR, Hemmanouil I, Wilkens L, Karstens H, Lenarz T: [Long term results in adenoidcystic carcinoma]. Laryngorhinootologie; 2002 Feb;81(2):98-105
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common symptoms were a tumor-related swelling and pain which persisted for a duration of several months after final diagnosis could be established.
  • No definitive differentiation was possible in 10 specimens.
  • The skull base was infiltrated in 16 patients.
  • Except one patient all 54 underwent surgical therapy.
  • Postoperative radiotherapy was additionally given in 25 cases which was combined with a chemotherapy in 6 patients.
  • Lymphnode metastases were observed in 13 patients after a latency of 3.3 years in average, but predominantly pulmonary metastases as distant spread developed in 18 patients after 5.8 years significantly later.
  • Male sex, infiltration of the skull base and histological evidence of perineural and perivascular spread proved to be statistically significant factors for an unfavourable prognosis.
  • CONCLUSIONS: Due to the uncommon biological behaviour with a slow growth on the one hand side and an aggressive local invasion on the other hand side the ACC can be regarded as a challenging malignant disease for the clinician whose adequate therapy does not allow any standardized regime.
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Laryngeal Neoplasms / diagnosis. Laryngeal Neoplasms / surgery. Laryngeal Neoplasms / therapy. Lymphatic Metastasis. Male. Middle Aged. Nasopharyngeal Neoplasms / diagnosis. Nasopharyngeal Neoplasms / surgery. Nasopharyngeal Neoplasms / therapy. Neoplasm Recurrence, Local. Parotid Neoplasms / diagnosis. Parotid Neoplasms / surgery. Parotid Neoplasms / therapy. Prognosis. Retrospective Studies. Submandibular Gland. Time Factors

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11914946.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement